CP
EOLS icon

Caligan Partners’s Evolus EOLS Stock Holding History

Caligan Partners’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,138,943
Closed -$25.4M – 28
2025
Q3 		$25.4M Buy
4,138,943
+796,973
+24% +$6.21M 3.33% 9
2025
Q2 		$30.8M Buy
3,341,970
+610,816
+22% +$6.25M 5.92% 6
2025
Q1 		$32.9M Buy
2,731,154
+38,766
+1% +$507K 6.86% 5
2024
Q4 		$29.7M Buy
2,692,388
+498,900
+23% +$7.02M 7.53% 4
2024
Q3 		$35.5M Buy
2,193,488
+25,698
+1% +$359K 11.26% 4
2024
Q2 		$23.5M Buy
2,167,790
+278,909
+15% +$3.43M 5.5% 7
2024
Q1 		$26.4M Buy
1,888,881
+571,025
+43% +$7.42M 6.99% 4
2023
Q4 		$13.9M Sell
1,317,856
-365,980
-22% -$3.27M 4.68% 6
2023
Q3 		$15.4M Sell
1,683,836
-76,300
-4% -$684K 7.07% 7
2023
Q2 		$12.8M Buy
1,760,136
+236,652
+16% +$2.04M 7.2% 7
2023
Q1 		$12.9M Sell
1,523,484
-217,216
-12% -$1.96M 8.99% 5
2022
Q4 		$13.1M Buy
+1,740,700
New +$13.5M 10.88% 3

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caligan Partners's EOLS Position: Q4 2025 in Review

Caligan Partners sold out of Evolus (EOLS) in Q4 2025, closing a stake of 4,138,943 shares — an estimated $25.4M sold.

Caligan Partners first reported a position in EOLS in Q4 2022 and held it in 12 quarters. The position peaked at $35.5M in Q3 2024. 169 funds tracked by Wall St. Rank hold EOLS as of Q4 2025.

  • Caligan Partners reported no remaining Evolus position as of Q4 2025 after selling out during the quarter.
  • Caligan Partners sold 4,138,943 Evolus shares in Q4 2025, an estimated $25.4M.
  • Caligan Partners first reported a position in Evolus in Q4 2022 and held it in 12 quarters.
  • Caligan Partners's Evolus position peaked at $35.5M in Q3 2024.
  • 169 funds tracked by Wall St. Rank held Evolus as of Q4 2025.

Based on Caligan Partners's 13F filing for Q4 2025, filed 17 Feb 2026.